PLoS ONE:miR-205可能是子宫内膜癌预后标记物

2012-04-20 Deepblue 生物谷

microRNAs已经被发现是基因表达的重要调控因子,它们改变基因表达的作用与癌症发生及肿瘤增殖密切相关。因此,microRNAs能够成为潜在的癌症标记物及治疗靶点。 虽然已有的证据表明了microRNAs的异常表达与子宫内膜癌有关,但是microRNAs对子宫内膜癌的预后意义有关的数据仍然有限。 近日,美国纽约州立石溪大学的研究人员做了一项关于microRNAs的研究。这项研究的目的在于,通

microRNAs已经被发现是基因表达的重要调控因子,它们改变基因表达的作用与癌症发生及肿瘤增殖密切相关。因此,microRNAs能够成为潜在的癌症标记物及治疗靶点。

虽然已有的证据表明了microRNAs的异常表达与子宫内膜癌有关,但是microRNAs对子宫内膜癌的预后意义有关的数据仍然有限。

近日,美国纽约州立石溪大学的研究人员做了一项关于microRNAs的研究。这项研究的目的在于,通过分析福尔马林固定的石蜡包埋的组织,来研究子宫内膜癌中有关的重要microRNAs的预后作用。

实验中,使用试剂盒提取了来自48对正常的及子宫内膜癌标本的总RNAs。其中,miR-26a、let-7g、miR-21、miR-181b、miR-200c、miR-192、miR-215、miR-200c及miR-205的表达通过实时定量RT-PCR分析。差异表达的miRNAs通过免疫组化被定量,数据分析则通过GraphPad Prism 5.0处理。

结果发现,对比于正常组织,miR-200c(P<0.0001)及miR-205(P<0.0001)的表达水平在子宫内膜瘤中被显著提高。

Kaplan-Meier生存分析显示,高水平的miR-205表达与不良的病人存活率有关(hazard ratio,0.377;Logrank test,P=0.028)。此外,在子宫内膜癌中发现,对比于正常组织,靶向抑癌基因(PTEN)的miR-205的表达下降。

这表明,在子宫内膜癌,miR-205将是一个很有潜能的子宫内膜癌预后标记物。相关论文发表在3月13日的PLoS ONE

免费全文下载PDF文件下载

doi: 10.1371/journal.pone.0035158
PMC:
PMID:

Prognostic Significance of miR-205 in Endometrial Cancer

Mihriban Karaayvaz, Cecilia Zhang, Sharon Liang, Kenneth R. Shroyer, Jingfang Ju.

microRNAs have emerged as key regulators of gene expression, and their altered expression has been associated with tumorigenesis and tumor progression.
Thus, microRNAs have potential as both cancer biomarkers and/or potential novel therapeutic targets.Although accumulating evidence suggests the role of aberrant microRNA expression in endometrial carcinogenesis, there are still limited data available about the prognostic significance of microRNAs in endometrial cancer.The goal of this study is to investigate the prognostic value of selected key microRNAs in endometrial cancer by the analysis of archival formalin-fixed paraffin-embedded tissues.Total RNAs were extracted from 48 paired normal and endometrial tumor specimens using Trizol based approach.The expression of miR-26a, let-7g, miR-21, miR-181b, miR-200c, miR-192, miR-215, miR-200c, and miR-205 were quantified by real time qRT-PCR expression analysis.Targets of the differentially expressed miRNAs were quantified using immunohistochemistry. Statistical analysis was performed by GraphPad Prism 5.0.The expression levels of miR-200c (P<0.0001) and miR-205 (P<0.0001) were significantly increased in endometrial tumors compared to normal tissues.Kaplan-Meier survival analysis revealed that high levels of miR-205 expression were associated with poor patient overall survival (hazard ratio, 0.377; Logrank test, P = 0.028).Furthermore, decreased expression of a miR-205 target PTEN was detected in endometrial cancer tissues compared to normal tissues.miR-205 holds a unique potential as a prognostic biomarker in endometrial cancer.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1072027, encodeId=bb1b10e2027c4, content=已阅,受益匪浅。, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6c905475903, createdName=湘雅科教, createdTime=Sat Nov 20 10:02:46 CST 2021, time=2021-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1930348, encodeId=5bc0193034839, content=<a href='/topic/show?id=22f61180211' target=_blank style='color:#2F92EE;'>#miR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11802, encryptionId=22f61180211, topicName=miR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a27288, createdName=smallant2002, createdTime=Thu Jul 12 20:13:00 CST 2012, time=2012-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1708277, encodeId=1ac41e0827747, content=<a href='/topic/show?id=4c2d3051535' target=_blank style='color:#2F92EE;'>#内膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30515, encryptionId=4c2d3051535, topicName=内膜)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=730431558473, createdName=12498974m61暂无昵称, createdTime=Thu Mar 21 04:13:00 CST 2013, time=2013-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1789414, encodeId=2abe1e89414ed, content=<a href='/topic/show?id=6e4814388e2' target=_blank style='color:#2F92EE;'>#Plos one#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14388, encryptionId=6e4814388e2, topicName=Plos one)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fda6311, createdName=119337457, createdTime=Sun May 06 18:13:00 CST 2012, time=2012-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1904397, encodeId=8a0e190439e75, content=<a href='/topic/show?id=b8aa619690e' target=_blank style='color:#2F92EE;'>#标记物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61969, encryptionId=b8aa619690e, topicName=标记物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1072181, createdName=wjywjy, createdTime=Sun Apr 22 22:13:00 CST 2012, time=2012-04-22, status=1, ipAttribution=)]
    2021-11-20 湘雅科教

    已阅,受益匪浅。

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1072027, encodeId=bb1b10e2027c4, content=已阅,受益匪浅。, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6c905475903, createdName=湘雅科教, createdTime=Sat Nov 20 10:02:46 CST 2021, time=2021-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1930348, encodeId=5bc0193034839, content=<a href='/topic/show?id=22f61180211' target=_blank style='color:#2F92EE;'>#miR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11802, encryptionId=22f61180211, topicName=miR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a27288, createdName=smallant2002, createdTime=Thu Jul 12 20:13:00 CST 2012, time=2012-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1708277, encodeId=1ac41e0827747, content=<a href='/topic/show?id=4c2d3051535' target=_blank style='color:#2F92EE;'>#内膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30515, encryptionId=4c2d3051535, topicName=内膜)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=730431558473, createdName=12498974m61暂无昵称, createdTime=Thu Mar 21 04:13:00 CST 2013, time=2013-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1789414, encodeId=2abe1e89414ed, content=<a href='/topic/show?id=6e4814388e2' target=_blank style='color:#2F92EE;'>#Plos one#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14388, encryptionId=6e4814388e2, topicName=Plos one)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fda6311, createdName=119337457, createdTime=Sun May 06 18:13:00 CST 2012, time=2012-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1904397, encodeId=8a0e190439e75, content=<a href='/topic/show?id=b8aa619690e' target=_blank style='color:#2F92EE;'>#标记物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61969, encryptionId=b8aa619690e, topicName=标记物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1072181, createdName=wjywjy, createdTime=Sun Apr 22 22:13:00 CST 2012, time=2012-04-22, status=1, ipAttribution=)]
    2012-07-12 smallant2002
  3. [GetPortalCommentsPageByObjectIdResponse(id=1072027, encodeId=bb1b10e2027c4, content=已阅,受益匪浅。, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6c905475903, createdName=湘雅科教, createdTime=Sat Nov 20 10:02:46 CST 2021, time=2021-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1930348, encodeId=5bc0193034839, content=<a href='/topic/show?id=22f61180211' target=_blank style='color:#2F92EE;'>#miR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11802, encryptionId=22f61180211, topicName=miR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a27288, createdName=smallant2002, createdTime=Thu Jul 12 20:13:00 CST 2012, time=2012-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1708277, encodeId=1ac41e0827747, content=<a href='/topic/show?id=4c2d3051535' target=_blank style='color:#2F92EE;'>#内膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30515, encryptionId=4c2d3051535, topicName=内膜)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=730431558473, createdName=12498974m61暂无昵称, createdTime=Thu Mar 21 04:13:00 CST 2013, time=2013-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1789414, encodeId=2abe1e89414ed, content=<a href='/topic/show?id=6e4814388e2' target=_blank style='color:#2F92EE;'>#Plos one#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14388, encryptionId=6e4814388e2, topicName=Plos one)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fda6311, createdName=119337457, createdTime=Sun May 06 18:13:00 CST 2012, time=2012-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1904397, encodeId=8a0e190439e75, content=<a href='/topic/show?id=b8aa619690e' target=_blank style='color:#2F92EE;'>#标记物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61969, encryptionId=b8aa619690e, topicName=标记物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1072181, createdName=wjywjy, createdTime=Sun Apr 22 22:13:00 CST 2012, time=2012-04-22, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1072027, encodeId=bb1b10e2027c4, content=已阅,受益匪浅。, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6c905475903, createdName=湘雅科教, createdTime=Sat Nov 20 10:02:46 CST 2021, time=2021-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1930348, encodeId=5bc0193034839, content=<a href='/topic/show?id=22f61180211' target=_blank style='color:#2F92EE;'>#miR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11802, encryptionId=22f61180211, topicName=miR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a27288, createdName=smallant2002, createdTime=Thu Jul 12 20:13:00 CST 2012, time=2012-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1708277, encodeId=1ac41e0827747, content=<a href='/topic/show?id=4c2d3051535' target=_blank style='color:#2F92EE;'>#内膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30515, encryptionId=4c2d3051535, topicName=内膜)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=730431558473, createdName=12498974m61暂无昵称, createdTime=Thu Mar 21 04:13:00 CST 2013, time=2013-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1789414, encodeId=2abe1e89414ed, content=<a href='/topic/show?id=6e4814388e2' target=_blank style='color:#2F92EE;'>#Plos one#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14388, encryptionId=6e4814388e2, topicName=Plos one)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fda6311, createdName=119337457, createdTime=Sun May 06 18:13:00 CST 2012, time=2012-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1904397, encodeId=8a0e190439e75, content=<a href='/topic/show?id=b8aa619690e' target=_blank style='color:#2F92EE;'>#标记物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61969, encryptionId=b8aa619690e, topicName=标记物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1072181, createdName=wjywjy, createdTime=Sun Apr 22 22:13:00 CST 2012, time=2012-04-22, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1072027, encodeId=bb1b10e2027c4, content=已阅,受益匪浅。, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6c905475903, createdName=湘雅科教, createdTime=Sat Nov 20 10:02:46 CST 2021, time=2021-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1930348, encodeId=5bc0193034839, content=<a href='/topic/show?id=22f61180211' target=_blank style='color:#2F92EE;'>#miR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11802, encryptionId=22f61180211, topicName=miR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a27288, createdName=smallant2002, createdTime=Thu Jul 12 20:13:00 CST 2012, time=2012-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1708277, encodeId=1ac41e0827747, content=<a href='/topic/show?id=4c2d3051535' target=_blank style='color:#2F92EE;'>#内膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30515, encryptionId=4c2d3051535, topicName=内膜)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=730431558473, createdName=12498974m61暂无昵称, createdTime=Thu Mar 21 04:13:00 CST 2013, time=2013-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1789414, encodeId=2abe1e89414ed, content=<a href='/topic/show?id=6e4814388e2' target=_blank style='color:#2F92EE;'>#Plos one#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14388, encryptionId=6e4814388e2, topicName=Plos one)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fda6311, createdName=119337457, createdTime=Sun May 06 18:13:00 CST 2012, time=2012-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1904397, encodeId=8a0e190439e75, content=<a href='/topic/show?id=b8aa619690e' target=_blank style='color:#2F92EE;'>#标记物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61969, encryptionId=b8aa619690e, topicName=标记物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1072181, createdName=wjywjy, createdTime=Sun Apr 22 22:13:00 CST 2012, time=2012-04-22, status=1, ipAttribution=)]
    2012-04-22 wjywjy

相关资讯

J Proteomics:化疗耐药乳腺癌的生物标志物

近日,英国赫尔大学研究人员鉴定出可能有助于预测乳腺癌患者化疗耐药的生物标志物。 化疗耐药是乳腺癌治疗的主要问题,许多癌症患者对化疗药物并不起反应。化疗耐药往往会使得其他更合适的治疗手段延后,病人接受治疗后都会有某些类型的副作用。 发表在《蛋白质组学》杂志上的文章表明,Hull研究人员已经鉴定一些抵抗常见的化疗药物包括表阿霉素和多西紫杉醇等相关的潜在生物标志物。 研究领导者Lynn Caw

Cancer Cell:雷公藤可能通过抑制MCL1基因治疗肿瘤

研究小组分析探讨了癌症中最常见的基因改变后,为开发抑制这种基因的药物奠定了关键基础。一项癌症遗传学研究指出MCL1基因所编码的蛋白质有助于保持细胞存活。这项新的研究针对抑制MCL1活性的化合物,并且研究了能预测肿瘤生存是否依赖于MCL1的一个重要伴侣基因。总之,该研究为开发靶向MCL1的新疗法铺平了道路。 Broad癌症计划项目Todd Golub、癌症研究所人类癌症基因研究者主任Charles

J Cell Bio:一个基因能遏制乳腺癌

近日,日本一个研究小组日前发布研究成果说,具有肿瘤抑制作用的乳腺癌易感基因BRCA1除可通过修复染色体异常来遏制乳腺癌和卵巢癌外,还能通过生成小核糖核酸来遏制癌症。这一成果可协助研究人员开发出新治疗药物。 乳腺癌易感基因BRCA1是近年来发现的一个肿瘤抑制基因,它的结构和功能变化与家族型乳腺癌和卵巢癌的发生有关。研究证实,BRCA1基因发生突变的人在40岁以前得乳腺癌的概率高达19%。&

肿瘤细胞免疫治疗策略

     郭亚军教授           相关幻灯资料   肿瘤细胞免疫治疗是继手术、放疗、化疗三大传统手段后的新支柱性治疗手段,最大的优势在于个体性、安全性、靶向性和高效性。肿瘤细胞免疫疗法并不能完全代替传统的治疗方法,但是可以起到辅助治疗作用,在手术、放化疗后获释患者放化疗间歇期使用肿瘤细胞免疫疗法效果较为显著。4月13日,在全国第五

PTPMeg2调节STAT3抑制乳腺癌

在最新一期国际权威乳腺癌杂志Breast Cancer Research上发表了清华大学常智杰教授研究组和孟坤博士合作的研究成果“Protein tyrosine phosphatase Meg2 dephosphorylates signal transducer and activator of transcription 3 and suppresses tumor growth

Cancer Cell:癌症凋亡细胞的突变种(BIK-DD)可引发胰腺癌干细胞凋亡

4月14日,台湾《联合晚报》报道说,台湾“中央研究院”院士洪明奇领导的研究团队从正常细胞中找到一种癌症凋亡细胞的突变种(BIK-DD),适度表现后,可引起癌症干细胞的凋亡,却不会误杀正常细胞,可望给几无存活机会的胰脏癌患者带来生机。 洪明奇14日出席相关研讨会并发表特别演讲,他的研究成果引起与会癌症医学专家热烈讨论。相关研究成果刊登在了国际杂志Cancer Cell上。 报道说,胰脏癌患者的5